Genome-wide methylation profiling reveals differentially methylated genes in blood DNA of small-cell lung cancer patients

作     者：Yanqi He Calvin Wei Zhifu Sun Julie M.Cunningham Liang Wang Zong Wei Ping Yang 

作者机构：Division of EpidemiologyDepartment of Quantitative Health SciencesMayo ClinicScottsdaleAZ 85259USA Department of Respiratory and Critical Care MedicineWest China HospitalSichuan UniversityChengdu 610041China Department of Physiology and Biomedical EngineeringMayo ClinicScottsdaleAZ 85259USA School of Molecular ScienceArizona State UniversityTempeAZ 85281USA Division of Computational BiologyDepartment of Quantitative Health SciencesMayo ClinicRochesterMN 55905USA Genomic Shared ResourceMayo Clinic Cancer CenterRochesterMN 55905USA Program of Tumor BiologyMoffitt Cancer CenterTampaFL 33612USA 

出 版 物：《Precision Clinical Medicine》 (精准临床医学（英文）)

年 卷 期：2022年第5卷第3期

页      面：192-194页

学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 

基　　金：support from Mayo Clinic Foundation and U.S.National Cancer Institute(Grants No.R03-77118 R01-80127 and R01-84354) 

主　　题：patients diagnosis cancer 

摘      要：Dear Editor,Small-cell lung cancer(SCLC),one of the most-deadly malignant tumors,accounts for∼15%of all lung cancers.1,2 Although highly responsive to the standard chemoradiotherapy,the recurrence rate of SCLC is nearly unity,with median survival time ranging from 2–6 *** all SCLC patients are inoperable,leading to the difficulty in obtaining adequate biopsy tissue for research.3 Consequently,there is an urgent need to find noninvasive biomarkers to predict the risk and provide early diagnosis of *** aimed to identify potential epigenomic markers for SCLC development in blood DNA and reveal differentially methylated genes through a multi-omics approach,from genome-wide DNA methylation profiling,followed by pathway enrichment analyses and target gene validation utilizing Gene Expression Omnibus(GEO)and Oncomine microarray databases,to TCGA PanCancer *** is known that virtually all patients with SCLC are victims of tobacco smoking,4 but it is unknown whether stopping smoking before SCLC diagnosis would influence the epigenetic biomarkers under *** here report a study that identified aberrantly methylated genes between current and former smokers among SCLC patients,revealing a set of candidate biomarkers in peripheral blood DNA for better stratifying patients with high risk.